Hessekiel Jeffrey bought CYTK
November 14, 2025 · Form 4 insider transaction
Hessekiel Jeffrey bought 87,297 shares of Cytokinetics, Incorporated at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 3 days after the transaction.
Footnotes
Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics.